"İstanbul Üniversitesi İstanbul Tıp Fakültesi Türkiye'nin sağlık eğitiminde öncü üniversitesi olarak Evrensel standartlara sahip nitelikli hekimler ve bilim insanları yetiştiren, ülkemize ve insanlığa yararlı bilgi üreten, kaliteli sağlık hizmeti sunan ve bu işlevleri etkin şekilde koordine eden öncü bir kurum olmak misyonuyla eğitim vermektedir."

During the past decade, Istanbul Universitesi Istanbul Tip Fakultesi Hastanesi conducted 8 clinical trials. In the 10-year time frame, 8 clinical trials started and 6 clinical trials were completed, i.e. on average, 75% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 4 clinical trials were completed. i.e. 200% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Istanbul Universitesi Istanbul Tip Fakultesi Hastanesi" #1 sponsor was "Celgene" with 3 trials, followed by "Takeda" with 3 trials sponsored, "Hoffmann-La Roche" with 2 trials sponsored, "Protagonist Therapeutics, Inc." with 2 trials sponsored and "Medtronic Cardiovascular" with 2 trials sponsored. Other sponsors include -5 different institutions and companies that sponsored additional 5 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Istanbul Universitesi Istanbul Tip Fakultesi Hastanesi" #1 collaborator was "Acceleron Pharma Inc. (a wholly owned subsidiary of Merck Sharp and Dohme, a subsidiary of Merck & Co., Inc.)" with 1 trials as a collaborator. Other collaborators include -1 different institutions and companies that were collaborators in the rest 1 trials.

According to Clinical.Site data, the most researched conditions in "Istanbul Universitesi Istanbul Tip Fakultesi Hastanesi" are "Multiple Myeloma" (3 trials), "Ineffective Erythropoiesis" (2 trials), "β-thalassemia" (2 trials), "Aortic Aneurysm, Abdominal" (1 trials) and "Autologous Stem Cell Transplant" (1 trials). Many other conditions were trialed in "Istanbul Universitesi Istanbul Tip Fakultesi Hastanesi" in a lesser frequency.

Most popular intervention types in "Istanbul Universitesi Istanbul Tip Fakultesi Hastanesi" are "Drug" (9 trials), "Other" (2 trials) and "Device" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (4 trials), "Cyclophosphamide" (2 trials), "Luspatercept" (2 trials), "PTG-300" (2 trials) and "Bendamustine" (1 trials). Other intervention names were less common.

The vast majority of trials in "Istanbul Universitesi Istanbul Tip Fakultesi Hastanesi" are 11 trials for "All" genders.

Currently, there are NaN active trials in "Istanbul Universitesi Istanbul Tip Fakultesi Hastanesi". undefined are not yet recruiting, 1 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 9 completed trials in Istanbul Universitesi Istanbul Tip Fakultesi Hastanesi, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Istanbul Universitesi Istanbul Tip Fakultesi Hastanesi, 0 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 6 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 0 trials that are defined as “Not Applicable".